Structure Therapeutics price target raised to $91 from $90 at JMP Securities

JMP Securities raised the firm’s price target on Structure Therapeutics to $91 from $90 and keeps an Outperform rating on the shares. The first 12-week weight loss data from the Phase 2a of GSBR-1290 in diabetics is set for December with data from the obese, non-diabetic cohort following in 1H24, and JMP thinks the 12-week weight loss data could surpass management’s 5% target, the analyst tells investors in a research note.